

Predisposition to Efficient Mammary Tumor Metastatic Progression Is Linked to the Breast Cancer Metastasis Suppressor Gene *Brms1*¹

Kent W. Hunter,² Karl W. Broman, Thomas Le Voyer, Luanne Lukes, Diana Cozma, Michael T. Debies, Jessica Rouse, and Danny R. Welch

Laboratory of Population Genetics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland 20892 [K. W. H., L. L., D. C., J. R.]; Department of Biostatistics, Johns Hopkins University, Baltimore, Maryland 21205 [K. W. B.]; Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [T. L. V.]; and Jake Gittlen Cancer Research Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033-2390 [M. T. D., D. R. W.]

ABSTRACT

Tumor metastasis is one of the most important clinical aspects of neoplastic disease because patient mortality is frequently attributable to disseminated rather than primary tumors. However, it still is not possible to definitively distinguish those individuals at high risk for disseminated disease, who would benefit from aggressive adjuvant therapy, from the low-risk patients who might be spared the side effects of additional anticancer therapy. To identify factors that predispose toward metastatic disease, we have used a genetic approach. Using a highly metastatic model of mammary cancer, we identified previously inbred mouse strains (DBA/2J, NZB/B1NJ, and I/LnJ) that harbor genetic factors that significantly suppress metastatic efficiency. In this study, we report the results of four experiments to localize the genetic map locations of the metastasis efficiency modifier genes. One statistically significant locus was identified on proximal Chr 19 designated *Mtes1*. Secondary candidate intervals were detected on Chrs 6, 9, 13, and 17. Interestingly, *Mtes1* colocalizes with the murine orthologue of the human breast cancer metastasis suppressor gene *Brms1*, suggesting that allelic variants of *Brms1* might be responsible for the metastasis suppression observed.

INTRODUCTION

The process of tumor dissemination or metastasis is an important aspect of clinical management of cancer. In most cases cancer patients with localized tumors have significantly better prognoses than those with disseminated tumors. The majority of cancer mortality has been associated with metastatic disease rather than the primary tumor (1). Because it has been estimated that 60–70% of patients have progressed to metastatic disease by the time of diagnosis (2), better understanding of the factors leading to tumor dissemination is of vital importance. The ability to identify those patients at high risk of metastatic disease may permit more aggressive therapy while sparing the low risk cohort the side effects of additional anticancer treatment.

The metastatic cascade is understandably complex, with many potential barriers. Successful tumor dissemination requires that tumor cells escape the primary tumor, invade the surrounding tissues, and are transported to secondary sites where they proliferate as secondary masses. Hemotogenous metastases enter into the vascular or lymphatic system and, once in the circulatory system, the cells must arrest in the target tissue, escape out of the blood vessel, and penetrate the adjacent tissue. Finally, the tumor cells must be able to proliferate in the foreign microenvironment and initiate angiogenic recruitment of new vasculature to allow the disseminated tumor to grow beyond microscopic size (1). An enormous amount of research has been performed elucidating various components of this process. As a result

a great deal is known about different molecules and pathways that are associated with metastatic progression, including activation of oncogenes (3, 4), recruitment of metalloproteases (5–8), and motility factors (9, 10). In addition, a number of chromosomal abnormalities have been associated with breast tumor dissemination in humans, including loss of Chrs³ 1p, 1q, 3p, 6q, 7q, 11p, and 11q (11). Metastasis-associated loss of heterozygosity has been used as a tool to identify members of a class of genes known as the metastasis suppressors. Analogous to tumor suppressors, metastasis suppressors can be distinguished from the former in that they prevent tumor dissemination when introduced into cancer cells but do not affect tumor initiation (12). To date, seven members of this class of genes have been described: *NM23* (13), *KISS1* (14), *KAI1* (15), E-cadherin (16), *MAP2K4* (17), *TIMPs* (18), Maspin (19), and *BRMS1* (12).

Despite this wealth of information, the critical initiating events or molecular pathways for tumor dissemination remain unclear. Part of the difficulty unraveling the complexity of metastasis may be attributable to multiple pathways converging on the same phenotype. Another confounding factor is likely to be genetic susceptibility to metastatic progression or genetic modulation of the efficiency of tumor dissemination. The presence of genetic modulation has been demonstrated both *in vitro* and *in vivo*. Tumors resulting from the transfection of oncogenes into cell lines derived from different mouse inbred strains show dramatically different metastatic abilities without affecting primary tumor formation (3). This suggested the presence of metastatic suppressing alleles in the genetic background of one mouse strain compared with a second metastatic mouse strain. We have demonstrated previously a significant impact of genetic background on the initiation, progression, and metastatic dissemination of the potent polyoma middle-T mammary tumor model. Alterations in tumor latency, tumor growth rate, and metastatic efficiency were observed in progeny of the F₁ generation of the PyMT bred to 27 different inbred strains (20). In the crosses analyzed to date it has been observed that the loci modulating the various phenotypes are genetically distinct (21, 22). Furthermore, different strain combinations can modify one, two, or three of the measured phenotypes, and, therefore, provide tools and reagents to specifically dissect the genetic components of various stages of mammary tumorigenesis.

Identification of key regulatory components of the metastatic process would serve two functions. First, they might provide more accurate prognostic markers of potential metastatic progression in patients than the current standards (23–32). Second, they may provide insights into the critical events in tumor dissemination, potentially leading to additional avenues of research or the development of novel therapies. Therefore, the current study describes the results of four different experiments to map the genetic components of efficient mammary tumor dissemination. Reproducible linkage to proximal Chr 19 was observed, linked to the breast cancer metastasis suppressor gene *Brms1*. Suggestive linkage to additional chromosomes was also uncovered.

³ The abbreviations used are: Chr, chromosome; QTL, quantitative trait loci; PI3k, phosphatidylinositol 3'-kinase.

Received 7/6/01; accepted 10/19/01.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported in part by an appropriation from the Commonwealth of Pennsylvania (to K. W. H.) and RO1 Grant CA88728 (to D. R. W.).

² To whom requests for reprints should be addressed, at Laboratory of Population Genetics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, 41/D702, 41 Center Drive, Bethesda, MD 20892. Phone: (301) 435-8957; Fax: (301) 435-8963; E-mail: Hunterk@mail.nih.gov.

MATERIALS AND METHODS

Animals. FVB/N-TgN(MMTVPyVT)^{634M^{ul}} mice were obtained from William Muller, McMaster University, Hamilton, Ontario, Canada (33). FVB/NJ, NZB/BINJ, DBA/2J, AKXD/TyJ, and I/LnJ mice were purchased from The Jackson Laboratory, Bar Harbor, Maine. The generation and genotyping of the I/LnJ backcross was described in Le Voyer *et al.* (21). The backcross (N₂) animals were generated by breeding FVB/N-TgN(MMTVPyVT)^{634M^{ul}} males to females of the other inbred strains (I/LnJ, DBA/2J, and NZB/BINJ), and the resulting transgene-positive F₁ males mated back to FVB/NJ females. Inheritance of the polyoma transgene was determined by PCR amplification of weanling tail biopsy DNA with the following primers: 5'-AAC GGC GGA GCG AGG AAC TG-3'; and 5'-ATC GGG CTC AGC AAC ACA AG-3'. The AKXD RI mapping experiment was performed by mating the FVB/N-TgN(MMTVPyVT)^{634M^{ul}} to females of each of the AKXD recombinant inbred lines and analyzing the transgene-positive female F₁ hybrids.

Determination of Metastatic Efficiency. Transgene-positive females were maintained at three to five animals per cage and screened by palpation three times a week for the presence of the primary mammary tumor. Diagnosis was performed by a single operator to minimize interpersonnel variance. The location of the tumor was recorded, and the animals were examined for an additional week to confirm diagnosis and then aged for 40 days after diagnosis to permit development of metastases. After 40 days, the animals were sacrificed by carbon dioxide inhalation and the lungs harvested for histological examination. The lung tissues were fixed in 10% paraformaldehyde, embedded in paraffin, sectioned, and stained with H&E. Three coronal nonadjacent sections of both lungs, each separated by 100 μ m, were prepared from each animal. The slides were examined with a Leica M420 Macroviewer with an Apozoom lens under $\times 10$ magnification with the objective 10 cm above the stage. Three fields were scored for each slide for a total of nine fields per animal. Pulmonary metastatic density was determined using a Leica Q500 MC Image Analysis System. The metastasis density was measured as the number of metastatic lesions per μ m² of lung tissue. The Q500 MC system was used to eliminate alveolar space from the measurement of lung tissue area to thereby control for various degrees of lung inflation at sacrifice. All of the slides were read blind and analyzed by a single operator to improve technical consistency.

Genotyping. Tail biopsy DNA was used as a template for PCR reactions. Microsatellite primers were purchased from Research Genetics (Huntsville, AL). PCR reactions were performed basically as described (21). Reactions were performed in a PTC200 Thermocycler (MJ Research, Watertown, MA) and analyzed on 4% agarose Tris-acetate-EDTA gels. The microsatellite loci used for genotyping are available on request.⁴

Statistical Analysis. The large number of animals with a pulmonary metastatic density of zero precluded use of traditional QTL mapping tools, which assume normally distributed values (34). An alternative nonparametric approach, in which trait values are replaced with ranks, is also not ideal for our data, because many individuals have identical trait values (35). To overcome these problems, we analyzed the survival time data using a recently described single-QTL model (36). In this model, mice with QTL genotypes AA and AB have probability p_A and p_B , respectively, of having metastases. If a mouse does have metastatic involvement, the log of the density of pulmonary metastases y is assumed to be normally distributed with mean μ_A or μ_B , according to its genotype, with a SD σ . To map the trait, we calculated three separate lod scores. The statistic lod(p) measures the probability of a mouse of a given genotype (p_A or p_B) having metastatic disease. The statistic lod(μ) measures differences in the average density of pulmonary metastases among those mice of a given genotype among those animals with metastatic involvement. The statistic lod(p, μ) is a combination of the lod(p) and lod(μ) scores and measures the combined efficiency of metastasis (the probability of having metastases as well as the density of metastatic lesions). In the AKXD RI lines, single-marker analyses were performed. In the three backcrosses, interval mapping was used. Significance thresholds were determined by permutation tests (37). In the three backcrosses, interval mapping was used. Significance thresholds were determined by permutation tests (37).

RESULTS

Previous studies demonstrated that the metastatic phenotype in F₁ hybrids between the PyMT mouse and AKR/J mice was not significantly different from that of the PyMT parent, whereas introduction of the DBA/2J genome significantly reduced the density of pulmonary metastatic lesions (see Fig. 1; Ref. 20). These results suggested the presence of metastatic efficiency suppressor alleles in the DBA/2J genome but not in the AKR/J genome. Therefore, the AKXD RI panel was used to try to identify candidate regions of the DBA/2J genome that suppressed metastatic efficiency. F₁ progeny were generated from 18 of the AKXD sublines (average 9.6/line; range 4–16), the pulmonary metastatic density determined and linkage analysis performed. Linkage analysis of the cross revealed two loci at which the LOD scores were substantially above the empirically determined genome-wide 5% threshold of significance (Fig. 2; Table 1). One of the key advantages of this RI backcross design is that the female F₁ progeny are isogenic but recombinant. The genetic structure of the RI backcross progeny resembles a conventional N₂ but with a much higher load of recombination breakpoints per genome. Therefore, the development and severity of tumor metastasis can be estimated accurately for each of the recombinant backcross progeny.

To additionally explore the genetic determinants of mammary tumor metastatic efficiency and to obtain confirmatory results (38)




Fig. 1. Example of the differences in metastatic density in different genetic backgrounds. Lung tissues were sectioned and stained with H&E. The metastases appear as dark staining lesions surrounded by normal lung parenchyma. A, FVB/NJ homozygous animal; B, DBA/2J F₁ animal.

⁴ Internet address: <http://www.nervenet.org/netpapers/Hunter/HunterN2.html>.




Fig. 2. Graphical representation of the probability plots for the AKXD QTL mapping data. The Chrs are represented along the X axis, with the centromere to the left of each segment. The LOD scores are indicated on the Y axis. A circle indicates the LOD score for each locus assayed. The horizontal dashed line represents the empirical 5% significance threshold determined by permutation testing. The LOD scores for the individual tests are depicted in the top two panels; the combined scores are represented in the bottom panel.

Table 1 LOD scores for AKXD RI mapping experiment

Chr 6				Chr 19			
Locus	LOD (μ)	LOD (p)	LOD (μ , p)	Locus	LOD (μ)	LOD (p)	LOD (μ , p)
Significance threshold ^a	2.88	2.68	3.49	Significance threshold ^a	2.88	2.68	3.49
<i>Mrv23</i>	0.52	0.26	0.77	<i>Cd98</i>	1.08	2.52	3.60
<i>D6Mit33</i>	3.31	0.32	3.63	<i>Cd5</i>	1.41	1.76	3.17
<i>Rn7s6</i>	0.99	0.80	1.79	<i>D19Mit41</i>	0.22	0.95	1.17
<i>D6Nds3</i>	0.22	0.74	0.96	<i>Rln</i>	0.00	2.30	2.31
<i>Tgfa</i>	0.00	0.12	0.12	<i>Jak2</i>	0.03	1.90	1.93
<i>D6Nds2</i>	0.01	0.05	0.06	<i>D19Mit40</i>	0.03	1.53	1.56
<i>Rho</i>	0.00	0.84	0.85	<i>Mbl2</i>	0.00	2.30	2.31
<i>Raf1</i>	0.36	1.20	1.55	<i>D19Mit21</i>	0.06	0.34	0.40
<i>D6Mit15</i>	0.27	0.02	0.29	<i>D19Mit38</i>	0.01	0.13	0.14
<i>Xmmv54</i>	0.05	0.00	0.05	<i>D19Mit35</i>	0.04	0.03	0.07

^a Genome-wide significance thresholds were determined by Permutation testing.

conventional backcross-mapping progeny were generated and analyzed. Previous studies demonstrated that F₁ hybrids between FVB/N-TgN(MMTV-PyMT)^{634Mut} and DBA/2J or NZB/B1NJ suppressed metastatic involvement ~10-fold compared with the FVB/NJ homozygous animals without altering tumor latency or tumor growth kinetics (20). Therefore, these strains are likely to contain modifier alleles that specifically affect the metastatic process. I/LnJ F₁ hybrids, in addition to suppressing metastatic density, also displayed altered tumor latency (38 days after birth versus 60 days; Ref. 21) and tumor burden (approximately 70–80%; Ref. 22) compared with FVB/NJ homozygotes. No evidence of a correlation between tumor latency with metastatic efficiency was observed (data not shown). A modest effect was observed for tumor growth rate ($r = 0.49$; Ref. 20), which reduces the power to detect metastasis specific modifier genes in these animals. However, this backcross was included in the analysis in the hope that there would be enough statistical power to detect one or more of the loci detected in the AKXD experiment at or above the recommended statistically suggestive threshold, thereby strengthening genomic localization data. The number of animals generated in each cross is indicated in Table 2.

Complete genome scans were performed for the backcrosses and

chromosomal associations with suppression of metastatic efficiency determined as above (see Table 3 and Fig. 3). The NZB backcross demonstrated suggestive linkage to the same region of 19 seen in the AKXD experiment. Suggestive linkage was also observed on distal

Table 2 Size of experimental crosses

Mapping experiment	Animals analyzed
I/LnJ	125
DBA/2J	177
NZB/B1NJ	69
AKXD	171
Total	544

Table 3 LOD scores for backcross analysis

Chromosome	DBA/2J	I/LnJ	NZB/B1NJ	Combined
9	1.6	1.5	2.1	5.2
13	1.7	0.2	1.7	3.6
17	0.3	2.4	3.0	5.6
19	0.5	1.0	2.3	3.8
Significant threshold ^a	3.0	3.2	3.2	5.9

^a Genome-wide significance thresholds were determined by Permutation testing.




Fig. 3. Graphical representation of the probability plots for the backcrosses. The Chrs are depicted along the X axis with the centromere at the origin. The LOD score is represented on the Y axis. The combined LOD score for the three crosses is represented by the D+I+N line. A, Chr 6; B, Chr 9; C, Chr 13; D, Chr 17; E, Chr 19.

Chr 17 and weaker linkage to Chr 13, as well as linkage to central Chr 9. The I/LnJ cross also exhibited suggestive linkage to distal Chr 17 as well as linkage to the proximal third of Chr 9. The DBA backcross also exhibited linkage for Chrs 9 and 13.

Surprisingly, in light of the AKXD experiment, no linkage was observed for suppression of metastatic efficiency and either the Chr 6

or Chr 19 loci in the DBA/2J backcross. Replication of the association between proximal Chr 19 in the NZB/B1NJ backcross strongly suggested the correct assignment of a metastatic efficiency modifier to this region. Previous studies in our and other laboratories (21, 39–41) have demonstrated the presence of unanticipated epistatic interactions in QTL analysis that might account for the discrepancy. Alternatively,

novel alleles may have become fixed in the inbred descendants of any of the inbred strains. Therefore, the genotype-phenotype correlation of the AKXD RI experiment was examined to determine which genome (AKR/J or DBA/2J) was associated with metastatic progression. Metastatic suppression at both loci was associated with the AKR/J rather than the DBA/2J alleles (see Fig. 4). Because the original strain survey demonstrated that (FVB/NJ \times AKR/J) F_1 animals were indistinguishable from FVB/NJ homozygous animals (20), the suppression attributable to these loci is most likely because of either epistatic interactions with DBA/2J loci or the presence of a locus in AKR/J that neutralizes the metastatic suppression in the (FVB/NJ \times AKR/J) F_1 hybrids that has been lost in the generation of the AKXD RI lines or recently gained in the AKR/J since the generation of the AKXD RI panel.

The coincident identification of the Chr 19 locus associated with metastatic suppression in the AKXD RI and NZB/BINJ backcross experiments strongly suggest the presence of a metastasis modifier at this location. Therefore, we have designated the Chr 19 locus as Metastasis efficiency suppressor 1 (*Mtes1*). Repeated identification of proximal 9 in all three of the backcrosses as well as the association of Chr 13 in the DBA/2J and NZB/BINJ backcrosses and Chr 17 in the I/LnJ and NZB/BINJ backcrosses suggests that there are likely to be

additional modifier loci present on these chromosomes as well. Although the Chr 6 locus achieved statistical significance in the analysis of the AKXD experiment, the unexpected association of suppression with the AKR/J allele and the lack of replication in the backcrosses increase the possibility that this linkage is attributable to chance rather than a genetic basis. Therefore, we have chosen to be conservative and consider this locus suggestive pending additional analysis.

To determine whether one of the known metastatic suppressor genes might be a candidate for the *Mtes1* locus, their genomic location was compared with the *Mtes1* mapping data. *Cd82*, E-cadherin, *Map2k4*, and the *Timp* genes did not colocalize with either *Mtes1* locus (42). The mouse homologue to *KISS1* has not been mapped. However, in humans the *KISS1* maps to 1q32, a region that retains homologous synteny with distal mouse Chr 1 and is, therefore, unlikely to be a candidate. The NM23 family members map to human Chrs 7, 16, and 17, and are, therefore, also excluded as candidates for *Mtes1*. *BRMS1* maps to human Chr 11q13, which is homologous to proximal mouse Chr 19. The mouse *Brms1* sequence was compared by BLAST (43) against the mouse dbest database to identify ESTs from the mouse genome. The EST accession numbers were then used to search The Jackson Laboratory T31 Mouse Radiation Hybrid Mapping database (44) to determine whether any had been localized. One EST, accession number AV003220, was found closely linked to *D19 Mit29*, which maps under the peak of the *Mtes1* QTL mapping data.

DISCUSSION

In this study we have described the generation and analysis of four different genetic mapping experiments (AKXD/Ty, DBA/2J, NZB/BINJ, and I/LnJ; see Table 2) to identify the approximate genomic location of metastasis efficiency genes before initiating high-resolution mapping studies and positional cloning strategies to identify the genes of interest. Because of the complexity of the process, it was anticipated that a large number of genes might influence tumor dissemination and that metastasis-suppressing alleles of these genes might not be shared among inbred strains from relatively diverse backgrounds. To increase the probability of detecting significant associations as well as hopefully identifying multiple metastasis regulatory genes, multiple mapping experiments were analyzed. Three of the experiments involved inbred strains that altered only the metastatic phenotype of the mammary tumor (DBA/2J, NZB/BINJ, and AKXD/Ty). The I/LnJ backcross altered tumor growth rate (22) and tumor latency (21), as well as metastatic efficiency. In the latter cross the reduction in metastatic efficiency was expected to be the result of both reduction in tumor volume as well as specific genetic modification of tumor dissemination. The reduced metastatic efficiency because of decreased tumor volume would reduce the power of these experiments to detect loci specifically affecting tumor dissemination. However, they were included in the analysis because it was anticipated that concordance between the backcrosses might potentially identify genomic regions specific to the metastatic process that might not be detected in any single experiment.

Analysis of the results of these experiments reveals a number of points. First, not surprisingly, metastatic efficiency is a complex multigenic trait. No single modifier gene accounts for the significant variation in metastatic efficiency between inbred strains. Second, the reproducibility of the localizations suggests that there is likely to be only one or two pathways, at least in this tumor-metastasis model, that effect metastatic potential. If there were significantly more pathways involved it is unlikely that the loci would be replicated in multiple crosses. The polyoma middle-T antigen interacts and activates the PI3k/Akt signaling pathways and it has been demonstrated recently that constitutively active Akt can rescue the tumorigenicity of a




Fig. 4. Representation of the genotype/phenotype correlation on metastatic efficiency in the AKXD RI experiment. Relative metastatic efficiency is depicted on the Y axis; the genotypes of the relevant Chrs 6 and 19 loci are indicated across the X axis. The "all" category represents both genotypes for either the Chr 6 or 19 loci.

mutant polyoma middle-T protein that is incapable of interacting with PI3k. Interestingly, although tumorigenicity is restored in the Akt transgenic animals, metastatic capacity is not, suggesting that one or more pathways downstream of PI3k are required for tumor dissemination (45). It is likely that components of this pathway or pathways are the metastasis modifiers detected in this study. Third, the *Mtes1* locus is likely to be specific for the metastatic process, not simply suppressing tumor dissemination by reducing tumor growth rates. Three of the mapping experiments were initiated using inbred strains that do not alter tumor growth kinetics (AKXD, NZB/BINJ, and DBA/2J); therefore, the loci detected are likely to be specific to the metastatic process. To confirm this, the data were reanalyzed with the tumor burden data to look for potential epistatic interactions that might affect growth kinetics. No significant associations were observed, additionally suggesting that the loci detected were specifically modifying tumor dissemination (data not shown). In addition, in the I/LnJ backcross the metastasis-associated chromosomes detected in this study were independent of the chromosomes that harbor tumor growth modifier alleles (22). Identification and characterization of these genes will hopefully, therefore, provide valuable insights into the specific events and mechanisms required for tumor cells to disseminate and develop into secondary lesions. Chromosomal substitution or congenic strains are currently being constructed to confirm each of the metastatic efficiency suppressor intervals, explore potential genetic interactions, and initiate high resolution mapping studies.

On the basis of the analogy of inherited mutations in tumor suppressor genes predisposing individuals to cancer, an analysis of the metastasis suppressor genes was carried out to determine whether any of the known metastasis suppressors might be a candidate for *Mtes1*. The genomic locations of the known metastasis suppressor genes were identified in the Mouse Genome Informatics database to see if they colocalized with *Mtes1*. Comparative mapping and mining of the Radiation Hybrid maps demonstrated that the *Brms1* locus colocalizes with the peak of the *Mtes1* mapping data. *Brms1* was identified as a gene commonly deleted in breast cancer metastases but not primary tumors and was shown to specifically suppress metastatic ability after transfection into highly metastatic cell lines. The colocalization of *Brms1* and the mammary tumor metastasis efficiency gene *Mtes1* raises the intriguing possibility that *Mtes1* might be an allelic form of *Brms1*. Genomic analysis of this locus is currently in progress. However, preliminary evidence suggests that the differences in metastatic susceptibility observed in the various strains is not likely to be attributable to significant differences in transcription levels of *Brms1* (data not shown).

The Chr 6 locus detected in the AKXD/Ty genetic mapping experiments was not replicated in the backcrosses, and, therefore, did not meet our stringent criteria applied to be assigned a locus designation. However, it is interesting to note that this region of the mouse genome contains homology to human Chr 7. In particular, the region between the loci *Mtv23* and *D6Mit33* (see Table 1), at the peak of the LOD score plots, is homologous to human 7q21–7q35, which, like the *BRMS1* region, is often deleted in metastatic breast cancer (31). The *Met* oncogene, which has been implicated in tumor dissemination in a number of studies (46–48), is also present on mouse Chr 6, although it is proximal to *Mtv23*, and, therefore, unlikely to be a candidate for the potential metastasis efficiency modifier gene that might lie in this region. No other obvious candidate genes (metastasis suppressors, metalloproteases, adhesion molecules, and so forth) reside in this region. Although the association of mouse equivalent of the human 7q metastasis-associated loss of heterozygosity region in this study is suggestive of the presence of a metastasis efficiency modifier, additional studies will be required to confirm the linkage studies by replication.

Although it is clearly too early to address the mechanism of the metastasis efficiency modifiers, the association of *Mtes1* with the mouse homologue of *BRMS1* raises an intriguing possibility. *BRMS1* was recently shown to restore gap junction to human breast carcinoma cells (49). None of the loci described in this study colocalize with members of the connexin family of gap junction proteins. However, we describe previously the mapping of tumor growth modifier genes in the I/LnJ cross to mouse Chr 4. Chr 4 harbors four known gap junction genes (*Gja3*, 4, 5, and 10; Ref. 42), two of which are known to colocalize with the major growth modifier peak (22). We had demonstrated previously that the total tumor mass at time of sacrifice had a modest effect on metastatic potential (20) and had attributed part of the reduction of metastatic efficiency of the I/LnJ backcross to an indirect effect of reduced tumor mass. However, the colocalization of connexin gene family members with this peak suggests that a more direct effect may be in responsible.

Finally, this study suggests that there are subsets of human breast cancer patients that have significantly elevated risks of tumor dissemination. This inherited predisposition would help explain why some patients with relatively small tumors have extensive disseminated disease, whereas other patients with larger tumors have only localized lesions. Additional research into the genetic basis of the differences in metastatic efficiency will have two potential benefits. First, identifying and characterizing the genes responsible for the different metastatic efficiencies will likely provide greater understanding of the mechanisms responsible for tumor dissemination. This may permit the development of better antimetastatic therapies or preventative interventions. Second, by identifying the underlying genetic basis of efficient metastatic spread, it may be possible to identify that subset of breast cancer patients who are at highest risk. These patients could be examined more thoroughly to search disseminated tumors that may not yet be clinically apparent in order to treat them at the time of primary therapy. In addition, high-risk patients could be followed up more carefully and frequently after treatment for the primary tumor, resulting earlier detection and treatment of recurrent disease. Furthermore, it might be possible to enroll high-risk patients in chemoprevention protocols to inhibit or prevent the growth of clinically occult lesions, reducing the morbidity and mortality associated with metastatic breast cancer.

ACKNOWLEDGMENTS

We thank Warren Kruger, Lisa Henske (Fox Chase Cancer Center, Philadelphia, PA), and Ken Buetow (NCI/NIH, Bethesda, MD) for useful discussion, and Beverly Mock (NCI/NIH, Bethesda, MD), Rob Williams (University of Tennessee, Memphis, TN), and the anonymous referees for critical review of this manuscript.

REFERENCES

- Liotta, L. A., and Stetler-Stevenson, W. G. Principles of molecular cell biology of cancer: Cancer metastasis. In: S. H. V. DeVita and S. A. Rosenberg (eds.), *Cancer: Principles and Practices of Oncology*, Fourth Ed., pp. 134–149. Philadelphia, PA: J. B. Lippincott Co., 1993.
- Eccles, S. A., Box, G., Court, W., Sandle, J., and Dean, C. J. Preclinical models for the evaluation of targeted therapies of metastatic disease. *Cell Biophys.*, 25: 279–291, 1994.
- Muschel, R. J., Williams, J. E., Lowy, D. R., and Liotta, L. A. Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell. *Am. J. Pathol.*, 121: 1–8, 1985.
- Otsuka, T., Takayama, H., Sharp, R., Celli, G., LaRochelle, W. J., Bottaro, D. P., Ellmore, N., Vieira, W., Owens, J. W., Anver, M., and Merlino, G. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. *Cancer Res.*, 58: 5157–5167, 1998.
- Zeng, Z. S., and Guillem, J. G. Unique activation of matrix metalloproteinase-9 within human liver metastasis from colorectal cancer. *Br. J. Cancer.*, 78: 349–353, 1998.

6. Olaso, E., Santisteban, A., Bidaurrezaga, J., Gressner, A. M., Rosenbaum, J., and Vidal-Vanaclocha, F. Tumor-dependent activation of rodent hepatic stellate cells during experimental melanoma metastasis. *Hepatology*, *26*: 634–642, 1997.
7. Tokuraku, M., Sato, H., Murakami, S., Okada, Y., Watanabe, Y., and Seiki, M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. *Int. J. Cancer*, *64*: 355–359, 1995.
8. Shi, Y. E., and Liu, Y. Stromal-epithelial interaction in type IV collagenase expression and activation: the role in cancer metastasis. *EXS (Basel)*, *74*: 215–234, 1995.
9. Silletti, S., Paku, S., and Raz, A. Autocrine motility factor and the extracellular matrix. II. Degradation or remodeling of substratum components directs the motile response of tumor cells. *Int. J. Cancer*, *76*: 129–135, 1998.
10. Silletti, S., Paku, S., and Raz, A. Autocrine motility factor and the extracellular matrix. I. Coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization. *Int. J. Cancer*, *76*: 120–128, 1998.
11. Welch, D. R., and Wei, L. L. Genetic and epigenetic regulation of human breast cancer progression and metastasis. *Endocrine-related Cancer*, *5*: 155–197, 1998.
12. Seraj, M. J., Samant, R. S., Verderame, M. F., and Welch, D. R. Functional evidence for a novel human breast carcinoma metastasis suppressor, *BRMS1*, encoded at chromosome 11q13. *Cancer Res.*, *60*: 2764–2769, 2000.
13. Steeg, P. S., Bevilacqua, G., Kopper, L., Thorgeirsson, U. P., Talmadge, J. E., Liotta, L. A., and Sobel, M. E. Evidence for a novel gene associated with low tumor metastatic potential. *J. Natl. Cancer Inst.*, *80*: 200–204, 1988.
14. Lee, J. H., Miele, M. E., Hicks, D. J., Phillips, K. K., Trent, J. M., Weissman, B. E., and Welch, D. R. *KiSS-1*, a novel human malignant melanoma metastasis-suppressor gene. *J. Natl. Cancer Inst.*, *88*: 1731–1737, 1996.
15. Guo, X. Z., Friess, H., Di Mola, F. F., Heinicke, J. M., Abou-Shady, M., Graber, H. U., Baer, H. U., Zimmermann, A., Korc, M., and Buchler, M. W. *KAI1*, a new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma. *Hepatology*, *28*: 1481–1488, 1998.
16. Mareel, M., Vlemingckx, K., Vermeulen, S., Bracke, M., and Van Roy, F. E-cadherin expression: a counterbalance for cancer cell invasion. *Bull. Cancer (Paris)*, *79*: 347–355, 1992.
17. Yoshida, B. A., Dubauskas, Z., Chekmareva, M. A., Christiano, T. R., Stadler, W. M., and Rinker-Schaeffer, C. W. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (*MKK4/SEK1*), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. *Cancer Res.*, *59*: 5483–5487, 1999.
18. McDonnell, S., and Matrisian, L. M. Stromelysin in tumor progression and metastasis. *Cancer Metastasis Rev.*, *9*: 305–319, 1990.
19. Seftor, R. E., Seftor, E. A., Sheng, S., Pemberton, P. A., Sager, R., and Hendrix, M. J. Maspin suppresses the invasive phenotype of human breast carcinoma. *Cancer Res.*, *58*: 5681–5685, 1998.
20. Lifsted, T., Le Voyer, T., Williams, M., Muller, W., Klein-Szanto, A., Buetow, K. H., and Hunter, K. W. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. *Int. J. Cancer*, *77*: 640–644, 1998.
21. Le Voyer, T., Lu, Z., Babb, J., Lifsted, T., Williams, M., and Hunter, K. An epistatic interaction controls the latency of a transgene-induced mammary tumor. *Mamm. Genome.*, *11*: 883–889, 2000.
22. Le Voyer, T., Rouse, J., Lu, Z., Lifsted, T., Williams, M., and Hunter, K. Three loci modify growth of a transgene-induced mammary tumor: suppression of proliferation associated with decreased microvessel density. *Genomics*, *74*: 253–261, 2001.
23. Amadori, M., Adami, F., Aitini, E., Rabbi, C., Zamagni, D., Mambrini, A., Martini, C., and Smerieri, F. Prognostic factors in breast carcinoma with negative axillary lymph nodes. *Recenti Prog. Med.*, *88*: 181–185, 1997.
24. Figueroa, J. A., Yee, D., and McGuire, W. L. Prognostic indicators in early breast cancer. *Am. J. Med. Sci.*, *305*: 176–182, 1993.
25. Reiss, M. Prognostic factors in primary breast cancer. *Conn. Med.*, *53*: 565–571, 1989.
26. Arslan, N., Serdar, M., Deveci, S., Ozturk, B., Narin, Y., Ilgan, S., Ozturk, E., and Ozguven, M. A. Use of CA15–3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis. *Ann. Nucl. Med.*, *14*: 395–399, 2000.
27. Carter, C. L., Allen, C., and Henson, D. E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. *Cancer (Phila.)*, *63*: 181–187, 1989.
28. Fisher, R. A. (ed.). *Statistical Methods for Research Workers.*, 13th Edition, pp. 99–101. New York: Hafner, 1958.
29. Moon, T. E., Jones, S. E., Bonadonna, G., Valagussa, P., Powles, T., Buzdar, A., and Montague, E. Development and use of a natural history data base of breast cancer studies. *Am. J. Clin. Oncol.*, *10*: 396–403, 1987.
30. Rosen, P. P., Groshen, S., and Kinne, D. W. Survival and prognostic factors in node-negative breast cancer: results of long-term follow-up studies. *J. Natl. Cancer Inst. Monogr.*, *11*: 159–162, 1992.
31. Stierer, M., Rosen, H. R., Weber, R., Marczell, A., Kornek, G. V., and Czerwenka, E. Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. *Surg. Gynecol. Obstet.*, *175*: 151–160, 1992.
32. Abner, A. L., Collins, L., Peiro, G., Recht, A., Come, S., Shulman, L. N., Silver, B., Nixon, A., Harris, J. R., Schnitt, S. J., and Connolly, J. L. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. *Cancer (Phila.)*, *83*: 2502–2508, 1998.
33. Guy, C. T., Cardiff, R. D., and Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. *Mol. Cell Biol.*, *12*: 954–961, 1992.
34. Lander, E. S., and Botstein, D. Mapping mendelian factors underlying quantitative traits using RFLP linkage maps. *Genetics*, *121*: 185–199, 1989.
35. Kruglyak, L., and Lander, E. S. A nonparametric approach for mapping quantitative trait loci. *Genetics*, *139*: 1421–1428, 1995.
36. Boyartchuk, V. L., Broman, K. W., Mosher, R. E., D'Orazio, S. E., Starnbach, M. N., and Dietrich, W. F. Multigenic control of *Listeria monocytogenes* susceptibility in mice. *Nat. Genet.*, *27*: 259–260, 2001.
37. Churchill, G. A., and Doerge, R. W. Empirical threshold values for quantitative trait mapping. *Genetics*, *138*: 963–971, 1994.
38. Belknap, J. K., Mitchell, S. R., O'Toole, L. A., Helms, M. L., and Crabbe, J. C. Type I and type II error rates for quantitative trait loci (QTL) mapping studies using recombinant inbred mouse strains. *Behav. Genet.*, *26*: 149–160, 1996.
39. Fijneman, R. J., de Vries, S. S., Jansen, R. C., and Demant, P. Complex interactions of new quantitative trait loci, *Sluc1*, *Sluc2*, *Sluc3*, and *Sluc4*, that influence the susceptibility to lung cancer in the mouse. *Nat. Genet.*, *14*: 465–467, 1996.
40. Fijneman, R. J., Jansen, R. C., van der Valk, M. A., and Demant, P. High frequency of interactions between lung cancer susceptibility genes in the mouse: mapping of *Sluc5* to *Sluc14*. *Cancer Res.*, *58*: 4794–4798, 1998.
41. Fijneman, R. J., van der Valk, M. A., and Demant, P. Genetics of quantitative and qualitative aspects of lung tumorigenesis in the mouse: multiple interacting Susceptibility to lung cancer (*Sluc*) genes with large effects. *Exp. Lung Res.*, *24*: 419–436, 1998.
42. Blake, J. A., Eppig, J. T., Richardson, J. E., Bult, C. J., and Kadin, J. A. The Mouse Genome Database (MGD): integration nexus for the laboratory mouse. *Nucleic Acids Res.*, *29*: 91–94, 2001.
43. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. Basic local alignment search tool. *J. Mol. Biol.*, *215*: 403–410, 1990.
44. Rowe, L. B., Barter, M. E., and Eppig, J. T. Cross-referencing radiation hybrid data to the recombination map: lessons from mouse chromosome 18. *Genomics*, *69*: 27–36, 2000.
45. Hutchinson, J., Jin, J., Cardiff, R. D., Woodgett, J. R., and Muller, W. J. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. *Mol. Cell Biol.*, *21*: 2203–2212, 2001.
46. Chen, B. K., Ohtsuki, Y., Furihata, M., Takeuchi, T., Iwata, J., Liang, S. B., and Sonobe, H. Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage. *Pathol. Res. Pract.*, *195*: 427–433, 1999.
47. Bardelli, A., Basile, M. L., Audero, E., Giordano, S., Wennstrom, S., Menard, S., Comoglio, P. M., and Ponzetto, C. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. *Oncogene*, *18*: 1139–1146, 1999.
48. Firon, M., Shaharabany, M., Altstock, R. T., Horev, J., Abramovici, A., Resau, J. H., Vande Woude, G. F., and Tsarfaty, I. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. *Oncogene*, *19*: 2386–2397, 2000.
49. Saunders, M. M., Seraj, M. J., Li, Z., Zhou, Z., Winter, C. R., Welch, D. R., and Donahue, H. J. Breast cancer metastatic potential correlates with a breakdown in homospesific and heterospesific gap junctional intercellular communication. *Cancer Res.*, *61*: 1765–1767, 2001.